GLPwatch
Papers (12034)
Page 105 of 201, ranked by citation count.
- Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials.
- Effect of a GLP-1 mimetic on the insulin response to oral sugar testing in horses.
- Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.
- Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence.
- Palatable food avoidance and acceptance learning with different stressors in female rats.
- The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model.
- Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus.
- Liraglutide preserves intracellular calcium handling in isolated murine myocytes exposed to oxidative stress.
- Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day.
- The GLP-1 analog exendin-4 modulates HSP72 expression and ERK1/2 activity in BTC6 mouse pancreatic cells.
- Letter to Editor. Re "de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer," Semaglutide a Potential Treatment for Serious Weight Gain From ALK Tyrosine Kinase Inhibitors?
- Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy.
- Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis.
- SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice.
- GLP-1 receptor agonist effects on normal and neoplastic pancreata.
- Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet.
- Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins.
- Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.
- Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study.
- Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption.
- Effects of exendin-4 and selenium on the expression of GLP-1R, IRS-1, and preproinsulin in the pancreas of diabetic rats.
- Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity.
- Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet-induced obesity.
- Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus.
- Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide.
- GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial.
- Association between Symptoms of Depression and Generalised Anxiety Disorder Evaluated through PHQ-9 and GAD-7 and Anti-Obesity Treatment in Polish Adult Women.
- Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials.
- Exenatide regulates inflammation and the production of reactive oxygen species via inhibition of S1PR2 synthesis.
- Exendin-4 modifies adipogenesis of human adipose-derived stromal cells isolated from omentum through multiple mechanisms.
- Differential protective effects of exenatide, an agonist of GLP-1 receptor and Piragliatin, a glucokinase activator in beta cell response to streptozotocin-induced and endoplasmic reticulum stresses.
- Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.
- The effectiveness and value of tirzepatide for type 2 diabetes mellitus.
- Glycosylation Improves the Proteolytic Stability of Exenatide.
- Liraglutide improves cognition function in streptozotocin-induced diabetic rats by downregulating β-secretase and γ-secretase and alleviating oxidative stress in HT-22 cells.
- EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
- Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy.
- Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!
- Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.
- Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying.
- Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.
- Semaglutide Mitigates Ischemic Brain Injury by Inhibiting Ferroptosis via Modulation of FoXO1 and DRP1 Pathways.
- Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial.
- Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial.
- Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro.
- Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.
- Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control.
- Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
- Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro.
- Dose-Dependent Efficacy and Safety of Tirzepatide for Weight Loss in Non-diabetic Adults With Obesity: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis.
- GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma.
- Exenatide Prevents Diet-induced Hepatocellular Injury in A CEACAM1-Dependent Mechanism.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
- Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.
- Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes.
- Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction.
- Controlling the uncontrolled variation in the diet induced obese mouse by microbiomic characterization.